BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For
information on access to our products, please call our customer service line at 1-800-469-0261.
BDSI makes support available for clinical studies developed and sponsored by independent investigators, as long as the studies demonstrate clear scientific merit and involve treatments for serious and debilitating chronic conditions. Support may include funding, product, or both.Areas of interest currently being explored include:
Sponsor-investigators are encouraged to submit study proposals for consideration. Please download the form and email it upon completion to ISR@bdsi.com.Download application form
BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.
BDSI provides financial assistance to support accredited or unaccredited independent education programming, including educational symposia, seminars, and/or sessions directed by certified healthcare professionals, where the grant recipient is solely responsible for developing the content and managing the educational program.
For more information, please download our PDF on independent medical education grants. Download now
This is an online medical resource for scientific and clinical information on BioDelivery Sciences products and is intended for healthcare providers practicing in the United States. If you have questions about investigator-sponsored research, please contact your Medical Science Liaison or complete the form below and hit Submit.
Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDeliveryRead more
RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021Read more
Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million , Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST TodayRead more